Compare Invesco S&P 500 High Div Low Volatility ETF (SPHD) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 High Div Low Volatility ETF vs Tango Therapeutics Inc. — how do they compare? Invesco S&P 500 High Div Low Volatility ETF trades at $49.88 (market cap $3.20B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Invesco S&P 500 High Div Low Volatility ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco S&P 500 High Div Low Volatility ETF for 126 Days and Tango Therapeutics Inc. for 0 Days on average.
| SPHD | TNGX | |
|---|---|---|
Market Cap | $3.20B | $3.75B |
Volume | 1,075,230 | 9,619,106 |
52-Week High | $53.55 | $32.90 |
52-Week Low | $46.96 | $7.50 |
Typical Hold Time | 126 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPHD, the Invesco S&P 500 High Dividend Low Volatility ETF, trades at $49.29, up 0.1% on the day. Technical indicators show a mixed picture with a bullish overall signal but bearish moving averages, while the RSI suggests mild overbought conditions. The ETF focuses on high dividend yields and low volatility, attracting income-focused investors, though recent news highlights performance comparisons with peers like SCHD.
The outlook for SPHD hinges on its dividend strategy amid market volatility. Opportunities include steady income for retirees, but risks involve underperformance versus growth-focused ETFs and sensitivity to interest rate changes. Investors should weigh the trade-off between yield and total return potential.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
